Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$1.52	$2.27	$1.40 ▼ $9.22	$36.37M	0.67	202,363 shs	179,753 shs
COYA Coya Therapeutics	$5.86	$4.80	$3.71 ▼ $7.75	$137.46M	0.51	183,905 shs	107,485 shs
GNLX Genelux	$2.99	$2.90	$2.29 ▼ $8.53	$134.07M	0.58	184,248 shs	195,980 shs
UNCY Unicycive Therapeutics	$5.73	$7.39	$3.71 ▼ $8.74	$156.96M	1.79	2.83 million shs	2.99 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	0.00%	-9.52%	-21.24%	-38.71%	-77.45%
COYA Coya Therapeutics	0.00%	+6.55%	+20.68%	+46.13%	+1.38%
GNLX Genelux	0.00%	+4.07%	-2.92%	+16.34%	+5.28%
UNCY Unicycive Therapeutics	0.00%	-19.64%	-22.88%	-17.32%	+23.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$1.52	$2.27	$1.40 ▼ $9.22	$36.37M	0.67	202,363 shs	179,753 shs
COYA Coya Therapeutics	$5.86	$4.80	$3.71 ▼ $7.75	$137.46M	0.51	183,905 shs	107,485 shs
GNLX Genelux	$2.99	$2.90	$2.29 ▼ $8.53	$134.07M	0.58	184,248 shs	195,980 shs
UNCY Unicycive Therapeutics	$5.73	$7.39	$3.71 ▼ $8.74	$156.96M	1.79	2.83 million shs	2.99 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	0.00%	-9.52%	-21.24%	-38.71%	-77.45%
COYA Coya Therapeutics	0.00%	+6.55%	+20.68%	+46.13%	+1.38%
GNLX Genelux	0.00%	+4.07%	-2.92%	+16.34%	+5.28%
UNCY Unicycive Therapeutics	0.00%	-19.64%	-22.88%	-17.32%	+23.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	2.33	Hold	$17.50	1,051.32% Upside
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	161.66% Upside
GNLX Genelux	2.50	Moderate Buy	$18.00	502.01% Upside
UNCY Unicycive Therapeutics	2.71	Moderate Buy	$27.40	378.18% Upside

Current Analyst Ratings Breakdown

Latest ACTU, COYA, UNCY, and GNLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2026	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Speculative Buy	$18.00 ➝ $13.00
7/1/2026	UNCY Unicycive Therapeutics	Noble Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$60.00 ➝ $50.00
6/30/2026	UNCY Unicycive Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$22.00
6/30/2026	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$22.00 ➝ $15.00
6/24/2026	ACTU Actuate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/12/2026	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
6/10/2026	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/9/2026	UNCY Unicycive Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/5/2026	COYA Coya Therapeutics	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/5/2026	COYA Coya Therapeutics	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/2/2026	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Speculative Buy	$15.00 ➝ $18.00

(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.34 per share	N/A
COYA Coya Therapeutics	$7.95M	17.29	N/A	N/A	$2.06 per share	2.84
GNLX Genelux	$10K	13,407.16	N/A	N/A	$0.30 per share	9.97
UNCY Unicycive Therapeutics	$680K	230.80	N/A	N/A	$1.41 per share	4.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$22.23M	-$0.97	N/A	N/A	N/A	N/A	-430.93%	-180.86%	N/A
COYA Coya Therapeutics	-$21.23M	-$1.15	N/A	N/A	N/A	-266.10%	-55.86%	-48.86%	8/11/2026 (Estimated)
GNLX Genelux	-$32.15M	-$0.85	N/A	N/A	N/A	N/A	-174.55%	-123.65%	8/6/2026 (Estimated)
UNCY Unicycive Therapeutics	-$26.56M	-$2.21	N/A	0.73	N/A	N/A	-134.69%	-84.51%	8/13/2026 (Estimated)

Latest ACTU, COYA, UNCY, and GNLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2026	Q1 2026	ACTU Actuate Therapeutics	-$0.23	-$0.24	-$0.01	-$0.24	N/A	N/A
5/12/2026	Q1 2026	COYA Coya Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$0.15 million	$0.25 million
5/12/2026	Q1 2026	UNCY Unicycive Therapeutics	-$0.4589	-$0.54	-$0.0811	-$0.54	$11.11 million	N/A
5/7/2026	Q1 2026	GNLX Genelux	-$0.18	-$0.20	-$0.02	-$0.20	$0.01 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	1.80	1.80
COYA Coya Therapeutics	N/A	15.02	15.02
GNLX Genelux	N/A	3.68	3.68
UNCY Unicycive Therapeutics	N/A	2.40	2.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
COYA Coya Therapeutics	39.75%
GNLX Genelux	37.33%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	57.98%
COYA Coya Therapeutics	6.10%
GNLX Genelux	7.50%
UNCY Unicycive Therapeutics	6.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	23.93 million	10.05 million	N/A
COYA Coya Therapeutics	6	23.46 million	22.03 million	Not Optionable
GNLX Genelux	10	44.84 million	41.48 million	Not Optionable
UNCY Unicycive Therapeutics	9	27.39 million	25.74 million	Not Optionable

ACTU, COYA, UNCY, and GNLX Headlines

Recent News About These Companies

HC Wainwright Has Negative Outlook for UNCY Q2 Earnings

July 3 at 8:11 AM | marketbeat.com

Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the Firm

July 2 at 1:14 PM | globenewswire.com

Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies

July 2 at 1:10 AM | finance.yahoo.com

UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

July 1, 2026 | businesswire.com

UNCY ALERT: Unicycive Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Encouraged to Contact the Firm

July 1, 2026 | globenewswire.com

US FDA declines to approve Unicycive's kidney disease drug

June 30, 2026 | reuters.com

UNCY stock crashed 45% today – why did FDA reject its kidney disease NDA for a second time?

June 30, 2026 | msn.com

Unicycive shares plunge after FDA issues complete response letter for kidney disease drug (UNCY)

June 30, 2026 | msn.com

UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval

June 30, 2026 | finance.yahoo.com

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

June 30, 2026 | globenewswire.com

Unicycive Therapeutics Receives FDA Complete Response Letter for Resubmitted OLC NDA, Citing Third-Party Manufacturing Deficiencies

June 30, 2026 | quiverquant.comQ

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

June 30, 2026 | globenewswire.com

Unicycive Therapeutics (NASDAQ:UNCY) Downgraded to Sell Rating by Wall Street Zen

June 27, 2026 | americanbankingnews.com

Unicycive Therapeutics, Inc. Common Stock (UNCY) Insider Activity

June 27, 2026 | nasdaq.com

UNCY Share News Today

June 24, 2026 | uk.investing.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 24, 2026 | americanbankingnews.com

Unicycive seeks to distinguish OLC in crowded CKD hyperphosphatemia market

June 22, 2026 | msn.com

Unicycive Expands At-The-Market Equity Offering Program

June 5, 2026 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Unicycive Therapeutics (UNCY)

June 5, 2026 | theglobeandmail.com

Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside

May 21, 2026 | seekingalpha.com

Unicycive Therapeutics Inc Ordinary Shares UNCY

May 16, 2026 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACTU, COYA, UNCY, and GNLX Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$1.52 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.57 +0.05 (+3.29%)

As of 07/2/2026 07:59 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Coya Therapeutics NASDAQ:COYA

$5.86 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$5.92 +0.06 (+1.01%)

As of 07/2/2026 06:29 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Genelux NASDAQ:GNLX

$2.99 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.00 +0.01 (+0.50%)

As of 07/2/2026 04:10 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Unicycive Therapeutics NASDAQ:UNCY

$5.73 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$5.62 -0.11 (-1.83%)

As of 07/2/2026 07:53 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACTU, COYA, UNCY, and GNLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACTU, COYA, UNCY, and GNLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACTU, COYA, UNCY, and GNLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACTU, COYA, UNCY, and GNLX Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

Coya Therapeutics NASDAQ:COYA

Genelux NASDAQ:GNLX

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACTU, COYA, UNCY, and GNLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACTU, COYA, UNCY, and GNLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACTU, COYA, UNCY, and GNLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACTU, COYA, UNCY, and GNLX Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

Coya Therapeutics NASDAQ:COYA

Genelux NASDAQ:GNLX

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools